A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Publication date: May 13, 2019

This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study.

Concepts Keywords
Breastfeeding Cancer therapy
Cancer Prior anti cancer
Center Open MUM Uveal melanoma
Central Nervous System Immunodeficiency syndrome
Colorectal Cancer Surgery
Contraceptive Cancer therapy
Cooperative Group Alternative therapies
Cytological Radiotherapy
Hepatitis Melanoma
Histological RTT
Hotspot Medicine
Immunodeficiency Health
Malignancy Clinical medicine
Melanoma Uveal melanoma
Metastases Cancer
Metastatic Radiation therapy
Microsatellite Treating cancer
MSI Pharmacokinetics
Mutation
Organ
Pharmacokinetics
Radiotherapy
Solid Tumor
Tolerability
Tumor
Uveal Melanoma
Virus

Semantics

Type Source Name
disease MESH Tumors
gene UNIPROT GNAQ
disease MESH multi
gene UNIPROT GNA11
disease MESH uveal melanoma
disease DOID uveal melanoma
disease DOID cutaneous melanoma
disease MESH colorectal cancer
disease DOID colorectal cancer
pathway BSID Colorectal cancer
disease MESH Diagnosis
disease DOID cancer
disease MESH metastases
disease MESH acquired immunodeficiency syndrome
disease DOID acquired immunodeficiency syndrome
disease MESH hepatitis B
disease DOID hepatitis B
pathway BSID Hepatitis B
disease MESH hepatitis C
disease DOID hepatitis C
pathway BSID Hepatitis C
gene UNIPROT NR4A2
gene UNIPROT ALG3
disease MESH Melanoma
disease DOID Melanoma
pathway BSID Melanoma

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *